Cipla shares surged nearly 8% today after the pharmaceutical major announced quarterly results on Wednesday, reporting a sharp 54% fall in profit.
Cipla share price advanced 7.87% after the opening bell trading at Rs 1,432 apiece. The scrip was trading 7.24 % higher by 9:23 a.m. The benchmark NSE Nifty 50 was up 0.67%.
In the January to March quarter, Cipla's net profit stood at Rs 555 crore, accounting for a downtick of 54% compared to the same period last year. The bottom line missed analyst estimate of Rs 716 crore. Margin also compressed significantly, going from 22.8% in Q4FY25 to just 14.6%. Cipla's revenue for the quarter stood at Rs 6,541 crore, marginally below the analyst estimate of Rs 6,701 crore. The topline actually saw a degrowth of 2.8% compared to the same period last year.
Kotak on Cipla
Maintain 'Buy'; with target of Rs 1625
Operationally in-line 4QFY26; delivers strong 15% yoy domestic growth
Robust H2FY27E in the offing; a tad softer FY27E margin guidance
US guidance springs a positive surprise
Morgan Stanley on Cipla
Maintain 'Underweight'; cut target price to Rs 1218 from Rs 1237
Weak Earnings; FY27 Remains a Transition Year
EBITDA margins down 250 bps QoQ due to high staff cost
Sustainability of gross margin improvement and launch timeline of peptide assets will be key to track
The US pipeline is strengthening, with gVentolin approval and multiple filings across peptides, respiratory, and complex generics
Goldman Sachs on Cipla
Maintain 'Neutral'; hike target price to Rs 1350 from Rs 1325
Q4 results came in below estimates
India and South Africa beats, US pipeline in focus for FY27
US business faces gRevlimid headwinds
One Africa gathers momentum
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
